Arbutus Biopharma (ABUS) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Join SI Premium – FREE
Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of $0.01, $0.05 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $10.74 million versus the consensus estimate of $1.61 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- FAA awards ASI $875 million contract to overhaul flight scheduling
- Trump praises IBM CEO
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
